LADENBURG THALMANN FINANCIAL SERVICES INC. - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 69 filers reported holding CTI BIOPHARMA CORP in Q1 2019. The put-call ratio across all filers is 1.28 and the average weighting 0.0%.

Quarter-by-quarter ownership
LADENBURG THALMANN FINANCIAL SERVICES INC. ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q4 2019$2,0001,110
+5450.0%
0.00%
Q3 2019$0200.0%0.00%
Q2 2019$0200.0%0.00%
Q1 2019$0200.0%0.00%
Q4 2018$0200.0%0.00%
Q3 2018$0200.0%0.00%
Q2 2018$0200.0%0.00%
Q1 2018$0200.0%0.00%
Q4 2017$0200.0%0.00%
Q3 2017$020
-83.3%
0.00%
Q2 2017$0
-100.0%
1200.0%0.00%
Q1 2017$1,0001200.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q1 2019
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 3,904,400$3,355,0002.31%
BVF INC/IL 6,929,690$5,955,0000.65%
CAXTON CORP 324,452$279,0000.32%
NEA Management Company, LLC 3,750,000$3,222,0000.23%
Orbimed Advisors 5,000,000$4,297,0000.07%
Fosun International Ltd 459,274$390,0000.03%
Paloma Partners Management Co 229,800$197,0000.00%
OXFORD ASSET MANAGEMENT LLP 127,602$110,0000.00%
LMR Partners LLP 54,931$47,0000.00%
Tower Research Capital LLC (TRC) 17,495$15,0000.00%
View complete list of CTI BIOPHARMA CORP shareholders